# Celldex Therapeutics Inc. (CLDX) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $29.71, market value $2.3 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Celldex Therapeutics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 1510.1×**. Each dollar of revenue is priced at 1510.1×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 3.3×**. The shares trade at 3.3× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -10.4%**. Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -49.1%**. Return on equity is negative because earnings are negative.
- **Return on assets: -44.4%**. Each dollar of assets produces -44.4% of profit.

## Growth
- **Revenue growth (1 yr): -78.0%** (3-yr -13.1%/yr, 5-yr -26.9%/yr). Revenue fell 78.0% over the last year, against -26.9% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): -59.2%**. Earnings per share fell 59.2%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Current ratio: 10.49** (quick 10.49). Current assets cover the next year's liabilities 10.49 times.
- **Altman Z-score: 25.72**. A Z-score of 25.72 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 1/9**. 1 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Celldex Therapeutics Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (14 analysts). 14 analysts cover Celldex Therapeutics Inc.; the consensus is strong_buy, with an average price target of $63.07 (+112% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 8.6%** (YTD 6.9%, 3-mo -23.0%). The shares are up 8.6% over twelve months including dividends.
- **From 52-week high: -34.2%** (34.4% above the low). Trading 34% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 41**. An RSI of 41 is neutral.
- **Beta (1 yr): 1.23** (volatility 53%). Beta of 1.23 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=CLDX · Page: https://foliofundamentals.com/stocks/cldx

Not investment advice.